Elanders AB
Elanders AB: Quarterly Report January – March 2025
Elanders AB: Quarterly Report January – March 2025
First quarter 2025
- Net sales amounted to MSEK 3,232 (3,268), which corresponded to an organic net sales reduction of two percent compared to the same period last year, excluding acquisitions and discontinued operations, and using unchanged exchange rates.
- Adjusted EBITA amounted to MSEK 133 (180), which equaled an adjusted EBITA margin of 4.1 (5.5) percent.
- Operating profit was impacted by one-off items of MSEK -87 (-26), which mainly referred to structural measures to meet a weaker market and over time improve the Group’s margins. The structural measures are expected to result in annual cost savings of around MSEK 145, of which around MSEK 81 in 2025.
- Adjusted net result amounted to MSEK -21 (32), corresponding to SEK -0.60 (0.89) per share.
- Operating cash flow adjusted for purchase prices for acquisitions amounted to MSEK 520 (641). Operating cash flow including acquisitions amounted to MSEK 503 (121).
- Cash conversion increased to 138 (137) percent, excluding purchase prices for acquisitions.
- Free cash flow per share was SEK 10.1 (13.8).
- Net debt decreased by MSEK 862 to MSEK 8,250 compared to MSEK 9,112 at the beginning of the year. Excluding effects from IFRS 16, net debt decreased by MSEK 345 to MSEK 3,686 compared to MSEK 4,031 at the beginning of the year.
- During the first quarter the existing credit agreement was extended, which is an important step in ensuring long-term growth and stability.
Further information can be found on Elanders’ website www.elanders.com or requested via e-mail info@elanders.com.
Questions concerning this report can be addressed to:
Magnus Nilsson
President and CEO
Phone: +46 31 750 07 50
Åsa Vilsson
CFO
Phone: +46 31 750 07 50
Elanders AB (publ)
(Company ID 556008-1621)
Flöjelbergsgatan 1 C
431 37 Mölndal, Sweden
Phone: +46 31 750 00 00
This information is information that Elanders AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 10:00 CET on 23 April 2025.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
MoonLake Immunotherapeutics AG25.4.2025 22:05:00 CEST | Press release
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29
T-knife Therapeutics25.4.2025 19:00:00 CEST | Press release
T-knife Therapeutics Presents Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting Demonstrating a Potential Best-in-Class PRAME Targeted TCR-T Therapy
Zymeworks Inc.25.4.2025 19:00:00 CEST | Press release
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
Sequana Medical NV25.4.2025 18:00:00 CEST | Press release
Press release: Transparency Notification from Shareholders
Sanoma Corp25.4.2025 17:30:00 CEST | Press release
SANOMA CORPORATION: ACQUISITION OF OWN SHARES 25 April 2025
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom